

FOR IMMEDIATE RELEASE



May 7, 2013
AnGes MG, Inc.

**NEDO Adopts Lymphedema Project of Collatogene[®] (DNA Plasmid with HGF Gene)
as its Venture Aid Program**

AnGes MG, Inc. ("AnGes") announced that the New Energy and Industrial Technology Development Organization (NEDO) has adopted AnGes's Collatogene[®] project, "Development for practical application of lymphedema treatment drug with HGF plasmid" as its "2012 Venture Aid Program to Promote Practical Application of Innovation."

The aim of NEDO's venture aid program is to support the development of the advanced technology seeds and unutilized technologies held by research and development-based venture companies. It aims to generate new businesses and employment opportunities by reducing their risks, and by promoting prompt application and commercialization.

The Collatogene[®] project adopted by NEDO is a clinical development project aiming for a practical application of innovative and causal therapy for lymphedema. Lymphedema is an intractable disease in which an impaired lymphatic system causes severe swelling and fluid retention in limbs by preventing lymphatic fluid from returning to lymph vessels. The existing treatment for lymphedema is only symptomatic and mainly focused on complex decongestive therapy, by massaging the affected limbs and using compression garments. Hepatocyte growth factor (HGF) plasmid, with its action to promote lymph vessel formation, has the potential to become causal treatment. Development and practical application of this novel treatment for lymphedema is highly desired from a medical perspective.

Under the aid program by NEDO, AnGes will pursue the development of this HGF plasmid drug and conduct a Phase I/II trial for primary lymphedema. In relation to the Phase I/II trial, as announced by AnGes on July 30, 2012, the Investigational New Drug (IND) application has already been accepted by the Pharmaceuticals and Medical Devices Agency (PMDA). The study will start upon completion of necessary preparations at the selected trial site.

AnGes will receive a maximum of 103,194,000 yen as grant, equivalent to two-thirds of the costs that will occur in the period subject to the aid program (April 30, 2013 to February 20, 2014). AnGes expects the receipt of grant money during the fiscal year ending

December 2014. Thus, this event will have no effect on business performance for the fiscal year 2013.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com</p>
